EP Patent

EP3842032A1 — A pharmaceutical formulation

Assigned to Zaklady Farmaceutyczne "polpharma" Spolka Akcyjna · Expires 2021-06-30 · 5y expired

What this patent protects

This invention relates to an ophthalmic formulation comprising lifitegrast, an amino compound, a tonicity-adjusting agent and water, wherein the formulation has an osmolality of 150-330 mOsm/kg.The invention also relates to lifitegrast salts comprising lifitegrast and an amino co…

USPTO Abstract

This invention relates to an ophthalmic formulation comprising lifitegrast, an amino compound, a tonicity-adjusting agent and water, wherein the formulation has an osmolality of 150-330 mOsm/kg.The invention also relates to lifitegrast salts comprising lifitegrast and an amino compound defined herein.

Drugs covered by this patent

Patent Metadata

Patent number
EP3842032A1
Jurisdiction
EP
Classification
—
Expires
2021-06-30
Drug substance claim
No
Drug product claim
No
Assignee
Zaklady Farmaceutyczne "polpharma" Spolka Akcyjna
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.